# First-in-Human Clinical Trial of STUP-001, an In Vivo Direct Cell Conversion Gene Therapy for AIS-A/B Chronic Spinal Cord Injury

> **NCT06922890** · PHASE1,PHASE2 · RECRUITING · sponsor: **Yonsei University** · enrollment: 9 (estimated)

## Conditions studied

- Spinal Cord Injury
- Chronic Spinal Cord Injury

## Interventions

- **DRUG:** STUP-001

## Key facts

- **NCT ID:** NCT06922890
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-30
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2025-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06922890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06922890, "First-in-Human Clinical Trial of STUP-001, an In Vivo Direct Cell Conversion Gene Therapy for AIS-A/B Chronic Spinal Cord Injury". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06922890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*